局所再発性または転移性鼻咽頭癌または鼻腔ナチュラルキラーT細胞リンパ腫患者の治療におけるボリノスタットとアザシチジン

基本情報

NCT ID: NCT00336063
ステータス: 実施中（募集終了）
試験のフェーズ: 第1相
試験タイプ: 介入
目標被験者数: 18
治験依頼者名: National Cancer Institute (NCI)

概要

This phase I trial studies the side effects and best dose of vorinostat when given together with azacitidine in treating patients with nasopharyngeal cancer or nasal natural killer T-cell lymphoma that has recurred (come back) at or near the same place as the original (primary) tumor, usually after a period of time during which the cancer could not be detected or has spread to other parts of the body. Drugs used in chemotherapy, such as vorinostat and azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Vorinostat and azacitidine also may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving vorinostat together with azacitidine may kill more cancer cells.

対象疾患

成人鼻型節外性NK/T細胞リンパ腫再発性上咽頭未分化癌ステージIV鼻咽頭角化扁平上皮癌 AJCC v7ステージIV上咽頭未分化癌 AJCC v7再発性鼻咽頭角化扁平上皮癌

介入

Azacitidine(DRUG)

Laboratory Biomarker Analysis(OTHER)

Pharmacological Study(OTHER)

Vorinostat(DRUG)

依頼者（Sponsor）

National Cancer Institute (Nci)(NIH)

実施施設 (2)

National Cancer Center Hospital

Tokyo, Japan

国立研究開発法人国立がん研究センター中央病院

Tokyo, Japan